{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T23:00:28Z","timestamp":1752102028948,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24"],"award-info":[{"award-number":["10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24","10\/104\/24"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"crossref","award":["Health and Care Research Scholarship"],"award-info":[{"award-number":["Health and Care Research Scholarship"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Nottingham University Hospitals NHS Trust Research & Innovation Award"},{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779"],"award-info":[{"award-number":["PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779","PG\/08\/083\/25779"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Intensive antiplatelet therapy did not reduce recurrent stroke\/transient ischaemic attack (TIA) events as compared with guideline treatment in the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial, but did increase the frequency and severity of bleeding. In this pre-specified analysis, we investigated predictors of bleeding and the association of bleeding with outcome. TARDIS was an international prospective randomised open-label blinded-endpoint trial in participants with ischaemic stroke or TIA within 48\u00a0h of onset. Participants were randomised to 30\u00a0days of intensive antiplatelet therapy (aspirin, clopidogrel, dipyridamole) or guideline-based therapy (either clopidogrel alone or combined aspirin and dipyridamole). Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none. Of 3,096 participants, bleeding severity was: fatal 0.4%, major 1.5%, moderate 1.2%, minor 11.4%, none 85.5%. Major\/fatal bleeding was increased with intensive as compared with guideline therapy: 39 vs. 17 participants, adjusted hazard ratio 2.21, 95% CI 1.24\u20133.93, <jats:italic>p<\/jats:italic>\u2009=\u20090.007. Bleeding events diverged between treatment groups in the 8\u201335\u00a0day period but not in the 0\u20137 or 36\u201390\u00a0day epochs. In multivariate analysis more, and more severe, bleeding events were seen with increasing age, female sex, pre-morbid dependency, increased time to randomisation, prior major bleed, prior antiplatelet therapy and in those randomised to triple vs guideline antiplatelet therapy. More severe bleeding was associated with worse clinical outcomes across multiple physical, emotional and quality of life domains.<\/jats:p><jats:p><jats:italic>Trial registration<\/jats:italic><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/ISRCTN47823388\">ISRCTN47823388<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41598-023-38474-2","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T10:02:28Z","timestamp":1689847348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia"],"prefix":"10.1038","volume":"13","clinical-trial-number":[{"clinical-trial-number":"isrctn47823388","registry":"10.18810\/isrctn"}],"author":[{"given":"Lisa J.","family":"Woodhouse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason P.","family":"Appleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanne","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob A.","family":"Dineen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J.","family":"England","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailash","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan A.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Ranta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thompson G.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola","family":"Sprigg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip M.","family":"Bath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"issue":"10123","key":"38474_CR1","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/S0140-6736(17)32849-0","volume":"391","author":"PM Bath","year":"2018","unstructured":"Bath, P. M. et al. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): A randomised, open-label, phase 3 superiority trial. Lancet 391(10123), 850\u2013859 (2018).","journal-title":"Lancet"},{"issue":"15","key":"38474_CR2","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1161\/CIRCULATIONAHA.113.003187","volume":"128","author":"KS Wong","year":"2013","unstructured":"Wong, K. S. et al. Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: An updated systematic review and meta-analysis. Circulation 128(15), 1656\u20131666 (2013).","journal-title":"Circulation"},{"issue":"10","key":"38474_CR3","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/eurheartj\/ehq021","volume":"31","author":"G Ducrocq","year":"2010","unstructured":"Ducrocq, G. et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur. Heart J. 31(10), 1257\u20131265 (2010).","journal-title":"Eur. Heart J."},{"issue":"9","key":"38474_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1212\/WNL.0000000000004289","volume":"89","author":"NA Hilkens","year":"2017","unstructured":"Hilkens, N. A. et al. Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S. Neurology 89(9), 936\u2013943 (2017).","journal-title":"Neurology"},{"issue":"3\u20134","key":"38474_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000453459","volume":"43","author":"P Amarenco","year":"2017","unstructured":"Amarenco, P. et al. The intracranial-B2LEED3S score and the risk of intracranial hemorrhage in ischemic stroke patients under antiplatelet treatment. Cerebrovasc. Dis. (Basel, Switzerland) 43(3\u20134), 145\u2013151 (2017).","journal-title":"Cerebrovasc. Dis. (Basel, Switzerland)"},{"key":"38474_CR6","first-page":"11","volume":"369","author":"SC Johnston","year":"2018","unstructured":"Johnston, S. C. et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. N. Engl. J. Med. 369, 11 (2018).","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"38474_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1215340","volume":"369","author":"Y Wang","year":"2013","unstructured":"Wang, Y. et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N. Engl. J. Med. 369(1), 11\u201319 (2013).","journal-title":"N. Engl. J. Med."},{"key":"38474_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.120.033040","author":"Z-X Li","year":"2021","unstructured":"Li, Z.-X. et al. P2Y12 inhibitors plus aspirin versus aspirin alone in patients with minor stroke or high-risk transient ischemic attack. Stroke https:\/\/doi.org\/10.1161\/STROKEAHA.120.033040 (2021).","journal-title":"Stroke"},{"issue":"11","key":"38474_CR9","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/S1474-4422(07)70250-8","volume":"6","author":"J Kennedy","year":"2007","unstructured":"Kennedy, J. et al. Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): A randomised controlled pilot trial. Lancet Neurol. 6(11), 961 (2007).","journal-title":"Lancet Neurol."},{"issue":"3","key":"38474_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1056\/NEJMoa1916870","volume":"383","author":"SC Johnston","year":"2020","unstructured":"Johnston, S. C. et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. N. Engl. J. Med. 383(3), 207\u2013217 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"38474_CR11","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1001\/jamaneurol.2021.2440","volume":"78","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Efficacy and safety of ticagrelor and aspirin in patients with moderate ischemic stroke: An exploratory analysis of the THALES randomized clinical trial. JAMA Neurol. 78(9), 1091\u20131098 (2021).","journal-title":"JAMA Neurol."},{"issue":"7","key":"38474_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1001\/jamaneurol.2019.0932","volume":"76","author":"H Tillman","year":"2019","unstructured":"Tillman, H. et al. Risk for major hemorrhages in patients receiving clopidogrel and aspirin compared with aspirin alone after transient ischemic attack or minor ischemic stroke: A secondary analysis of the POINT randomized clinical trial. JAMA Neurol. 76(7), 774\u2013782 (2019).","journal-title":"JAMA Neurol."},{"issue":"5","key":"38474_CR13","first-page":"485","volume":"4","author":"IST-3 collaborative group","year":"2015","unstructured":"IST-3 collaborative group. Association between brain imaging signs, early and late outcomes, and response to intravenous alteplase after acute ischaemic stroke in the third International Stroke Trial (IST-3): Secondary analysis of a randomised controlled trial. Lancet Neurol. 4(5), 485\u201396 (2015).","journal-title":"Lancet Neurol."},{"issue":"12","key":"38474_CR14","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/jnnp-2020-323015","volume":"91","author":"C Delcourt","year":"2020","unstructured":"Delcourt, C. et al. Brain imaging abnormalities and outcome after acute ischaemic stroke: The ENCHANTED trial. J. Neurol. Neurosurg. Psychiatry 91(12), 1290\u20131296 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"3","key":"38474_CR15","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/STROKEAHA.117.019259","volume":"49","author":"NA Hilkens","year":"2018","unstructured":"Hilkens, N. A., Li, L., Rothwell, P. M., Algra, A. & Greving, J. P. External validation of risk scores for major bleeding in a population-based cohort of transient ischemic attack and ischemic stroke patients. Stroke 49(3), 601\u2013606 (2018).","journal-title":"Stroke"},{"issue":"1","key":"38474_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1186\/s12874-021-01388-6","volume":"21","author":"LJ Woodhouse","year":"2021","unstructured":"Woodhouse, L. J. et al. Statistical reanalysis of vascular event outcomes in primary and secondary vascular prevention trials. BMC Med. Res. Methodol. 21(1), 218 (2021).","journal-title":"BMC Med. Res. Methodol."},{"issue":"12","key":"38474_CR17","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","volume":"76","author":"Y Pan","year":"2019","unstructured":"Pan, Y. et al. Outcomes associated with clopidogrel-aspirin use in minor stroke or transient ischemic attack: A pooled analysis of clopidogrel in high-risk patients with acute non-disabling cerebrovascular events (CHANCE) and platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trials. JAMA Neurol. 76(12), 1466\u20131473 (2019).","journal-title":"JAMA Neurol."},{"key":"38474_CR18","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/ijs.12538","volume":"10","author":"The TARDIS Trial Investigators","year":"2015","unstructured":"The TARDIS Trial Investigators. Safety and efficacy of intensive vs. guideline antiplatelet therapy in high-risk patients with recent ischemic stroke or transient ischemic attack: Rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388). Int. J. Stroke 10, 1159\u20131165 (2015).","journal-title":"Int. J. Stroke"},{"issue":"3","key":"38474_CR19","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ijs.12445","volume":"10","author":"P Bath","year":"2015","unstructured":"Bath, P. et al. Statistical analysis plan for the \u201cTriple Antiplatelets for Reducing Dependency after Ischaemic Stroke\u201d (TARDIS) trial. Int. J. Stroke 10(3), 449\u2013451 (2015).","journal-title":"Int. J. Stroke"},{"issue":"5","key":"38474_CR20","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1177\/1747493016677988","volume":"12","author":"PM Bath","year":"2017","unstructured":"Bath, P. M. et al. Baseline characteristics of the 3096 patients recruited into the \u2018Triple Antiplatelets for Reducing Dependency after Ischemic Stroke\u2019trial. Int. J. Stroke 12(5), 524\u2013538 (2017).","journal-title":"Int. J. Stroke"},{"key":"38474_CR21","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1212\/WNL.53.1.126","volume":"53","author":"HP Adams","year":"1999","unstructured":"Adams, H. P. et al. Baseline NIH stroke scale score strongly predicts outcome after stroke. A report of the trial of Org 10172 in Acute Stroke Treatment (TOAST). Neurology 53, 126\u2013131 (1999).","journal-title":"Neurology"},{"issue":"9558","key":"38474_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(07)60150-0","volume":"369","author":"SC Johnston","year":"2007","unstructured":"Johnston, S. C. et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 369(9558), 283\u2013292 (2007).","journal-title":"Lancet"},{"issue":"8756","key":"38474_CR23","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/0140-6736(91)93206-O","volume":"337","author":"J Bamford","year":"1991","unstructured":"Bamford, J., Sandercock, P., Dennis, M., Burn, J. & Warlow, C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 337(8756), 1521\u20131526 (1991).","journal-title":"Lancet"},{"issue":"9968","key":"38474_CR24","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0140-6736(14)61121-1","volume":"385","author":"The ENOS Trial Investigators","year":"2015","unstructured":"The ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): A partial-factorial randomised controlled trial. The Lancet 385(9968), 617\u2013628 (2015).","journal-title":"The Lancet"},{"key":"38474_CR25","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1212\/WNL.0000000000008881","volume":"94","author":"JP Appleton","year":"2020","unstructured":"Appleton, J. P. et al. Imaging markers of small vessel disease and brain frailty, and outcomes in acute stroke. Neurology 94, e439\u2013e452 (2020).","journal-title":"Neurology"},{"issue":"10","key":"38474_CR26","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1161\/STROKEAHA.107.509893","volume":"39","author":"PMW Bath","year":"2008","unstructured":"Bath, P. M. W., Geeganage, C. M., Gray, L. J., Collier, T. & Pocock, S. Use of ordinal outcomes in vascular prevention trials: Comparison with binary outcomes in published stroke trials. Stroke 39(10), 2817\u20132823 (2008).","journal-title":"Stroke"},{"issue":"4","key":"38474_CR27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S. & Kearon, C. Int Society Thrombosis H. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thromb. Haemost. 3(4), 692 (2005).","journal-title":"J. Thromb. Haemost."},{"issue":"3","key":"38474_CR28","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/j.1747-4949.2012.00773.x","volume":"7","author":"PD Schellinger","year":"2012","unstructured":"Schellinger, P. D. et al. Assessment of addtional endpoints relevant to the benefit of patients after stroke - what, when, where, in whom. Int. J. Stroke 7(3), 227\u2013230 (2012).","journal-title":"Int. J. Stroke"},{"key":"38474_CR29","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1161\/01.STR.30.8.1538","volume":"30","author":"G Sulter","year":"1999","unstructured":"Sulter, G., Steen, C. & de Keyser, J. Use of the Barthel Undex and modified Rankin Scale in acute stroke trials. Stroke 30, 1538\u20131541 (1999).","journal-title":"Stroke"},{"key":"38474_CR30","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.0.CO;2-8","volume":"17","author":"K Bolland","year":"1998","unstructured":"Bolland, K., Sooriyarachchi, M. R. & Whitehead, J. Sample size review in a head injury trial with ordered categorical responses. Stat. Med. 17, 2835\u20132847 (1998).","journal-title":"Stat. Med."},{"key":"38474_CR31","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/gps.930091006","volume":"9","author":"DW Desmond","year":"1994","unstructured":"Desmond, D. W., Tatemichi, T. K. & Hanzawa, L. The telephone interview for cognitive status (TICS): Reliability and validity in a stroke sample. Int. J. Geriatr. Psychiatry 9, 803\u2013807 (1994).","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"2","key":"38474_CR32","first-page":"167","volume":"14","author":"T Tombaugh","year":"1999","unstructured":"Tombaugh, T., Kozak, J. & Rees, L. Normative data stratified by age and education for two measures of verbal fluency: FAS and animal naming. Arch Clin Neuropsychol. 14(2), 167\u2013177 (1999).","journal-title":"Arch Clin Neuropsychol."},{"issue":"1","key":"38474_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","volume":"37","author":"R Brooks","year":"1996","unstructured":"Brooks, R. EuroQol: The current state of play. Health Policy 37(1), 53\u201372. https:\/\/doi.org\/10.1016\/0168-8510(96)00822-6 (1996).","journal-title":"Health Policy"},{"key":"38474_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/archpsyc.1965.01720310065008","volume":"12","author":"WWK Zung","year":"1965","unstructured":"Zung, W. W. K. A self-rating depression scale. Arch. Gen. Psychiatry. 12, 63\u201370 (1965).","journal-title":"Arch. Gen. Psychiatry."},{"issue":"2","key":"38474_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/sim.2929","volume":"27","author":"MJ Pencina","year":"2008","unstructured":"Pencina, M. J., D\u2019Agostino, R. B. & Vasan, R. S. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat. Med. 27(2), 157\u201372 (2008).","journal-title":"Stat. Med."},{"issue":"1","key":"38474_CR36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/sim.4085","volume":"30","author":"MJ Pencina","year":"2011","unstructured":"Pencina, M. J., D\u2019Agostino, R. B. & Steyerberg, E. W. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 30(1), 11\u201321 (2011).","journal-title":"Stat Med."},{"issue":"10","key":"38474_CR37","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1001\/jama.2015.11082","volume":"314","author":"M Pencina","year":"2015","unstructured":"Pencina, M. & D\u2019Agostino, R. Evaluating discrimination of risk prediction models: The C statistic. JAMA 314(10), 1063\u20131064 (2015).","journal-title":"JAMA"},{"key":"38474_CR38","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman, S. & Kearon, C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J. Thrombosis Haemostasis. 3, 592\u2013694 (2005).","journal-title":"J. Thrombosis Haemostasis."},{"issue":"7","key":"38474_CR39","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/j.1532-5415.1992.tb01962.x","volume":"40","author":"MD Roccaforte","year":"1992","unstructured":"Roccaforte, M. D., Burke, W. J., Bayer, B. L. & Wengel, S. P. Validation of a telephone version of the mini-mental state examination. J. Am. Geriatr. Soc. 40(7), 697\u2013702 (1992).","journal-title":"J. Am. Geriatr. Soc."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38474-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38474-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T10:14:50Z","timestamp":1689848090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38474-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38474"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38474-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"16 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LJW and JPA were funded in part by NIHR TARDIS (10\/104\/24). JPA was supported, in part, by a NIHR Health and Care Research Scholarship, and is supported by a Nottingham University Hospitals NHS Trust Research & Innovation Award. TGR is a NIHR Senior Investigator. PMB is Stroke Association Professor of Stroke Medicine and an emeritus NIHR Senior Investigator; he has consulted for DiaMedica, Moleac, Phagenesis and Roche. Remaining authors (HC, RAD, TJE, MJ, KK, AAM, AR, NS) report no declarations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11717"}}